ERIS - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 2.6
| Stock Code | ERIS | Market Cap | 20,071 Cr. | Current Price | 1,448 ₹ | High / Low | 1,888 ₹ |
| Stock P/E | 79.0 | Book Value | 231 ₹ | Dividend Yield | 0.51 % | ROCE | 11.1 % |
| ROE | 8.89 % | Face Value | 1.00 ₹ | DMA 50 | 1,379 ₹ | DMA 200 | 1,436 ₹ |
| Chg in FII Hold | -0.46 % | Chg in DII Hold | 0.04 % | PAT Qtr | -8.60 Cr. | PAT Prev Qtr | 17.0 Cr. |
| RSI | 61.8 | MACD | 13.7 | Volume | 1,09,041 | Avg Vol 1Wk | 58,287 |
| Low price | 1,200 ₹ | High price | 1,888 ₹ | PEG Ratio | -5.84 | Debt to equity | 0.66 |
| 52w Index | 36.1 % | Qtr Profit Var | -128 % | EPS | 17.6 ₹ | Industry PE | 32.5 |
📊 ERIS shows weak fundamentals and high risk for swing trading. The P/E ratio (79.0) is far above industry average (32.5), suggesting overvaluation. ROCE (11.1%) and ROE (8.89%) are low, and debt-to-equity is relatively high at 0.66. PAT turned negative (-8.6 Cr vs 17 Cr), with quarterly profit variation at -128%, indicating severe earnings weakness. RSI at 61.8 is neutral to slightly overbought, MACD at 13.7 shows mild bullishness, and volume is higher than average, suggesting short-term activity. Despite EPS of 17.6 ₹ and dividend yield of 0.51%, fundamentals remain poor.
💡 Optimal Entry Price: Around 1,350–1,380 ₹ (near 50 DMA support).
📈 Exit Strategy: If already holding, consider exiting near 1,500–1,550 ₹ (short-term resistance) or cut losses if earnings weakness persists.
Positive
- 📌 [EPS Support](ca://s?q=ERIS_EPS): EPS of 17.6 ₹ provides some valuation backing.
- 📌 [Dividend Yield](ca://s?q=ERIS_dividend_yield): Yield of 0.51% offers shareholder returns.
- 📌 [Volume Strength](ca://s?q=ERIS_trading_volume): Current trading volume is higher than 1-week average, showing short-term interest.
Limitation
- ⚠️ [High Valuation](ca://s?q=ERIS_high_PE): P/E ratio of 79.0 is far above industry average (32.5).
- ⚠️ [Weak Profitability](ca://s?q=ERIS_low_ROCE_ROE): ROCE at 11.1% and ROE at 8.89% are poor.
- ⚠️ [High Debt](ca://s?q=ERIS_debt_equity): Debt-to-equity ratio of 0.66 raises financial risk.
Company Negative News
- ❌ [Profit Turned Negative](ca://s?q=ERIS_profit_loss): PAT dropped to -8.6 Cr from 17 Cr.
- ❌ [Quarterly Profit Collapse](ca://s?q=ERIS_quarterly_profit_variation): Profit variation at -128% shows severe weakness.
- ❌ [FII Exit](ca://s?q=ERIS_FII_exit): Foreign investors reduced holdings by 0.46%.
Company Positive News
- ✅ [Dividend Yield](ca://s?q=ERIS_dividend_yield): Yield of 0.51% provides shareholder returns.
- ✅ [Market Cap Strength](ca://s?q=ERIS_market_cap): Market cap of 20,071 Cr indicates industry relevance.
Industry
- 🏭 [Industry PE](ca://s?q=Pharma_industry_PE): Industry average P/E is 32.5, much lower than ERIS’s valuation.
- 🏭 [Sector Outlook](ca://s?q=Pharma_sector_outlook): Pharma sector benefits from steady demand and healthcare expansion, but company-specific weakness limits upside.
Conclusion
📉 ERIS is a weak candidate for swing trading. Fundamentals are poor, profitability has collapsed, and valuation is stretched. Entry near 1,350–1,380 ₹ may offer a cautious setup, but upside is limited to 1,500–1,550 ₹. Risks include negative PAT, high debt, and overvaluation, making this stock suitable only for high-risk traders with strict stop-loss discipline.